Ultragenyx Pharmaceutical
RARE
253 hedge funds and large institutions have $9.37B invested in Ultragenyx Pharmaceutical in 2020 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 97 increasing their positions, 72 reducing their positions, and 16 closing their positions.
288% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 16
267% more call options, than puts
Call options by funds: $59.6M | Put options by funds: $16.3M
80% more capital invested
Capital invested by funds: $5.2B → $9.37B (+$4.17B)
35% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 72
22% more funds holding
Funds holding: 207 → 253 (+46)
2.09% less ownership
Funds ownership: 104.36% → 102.28% (-2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$133M |
| 2 |
BlackRock
New York
|
+$56.7M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$56.7M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$52.7M |
| 5 |
Goldman Sachs
New York
|
+$51.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$67.4M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$23.2M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$23M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$20.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$16.7M |
RARE Hedge Fund Activity: Q4 2020 in Review
253 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2020, worth a combined $9.37B — up 80% from $5.2B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new RARE positions and 16 closed out — a net gain of 46 holders — while 97 added to existing stakes and 72 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $133M. The largest seller was Alkeon Capital Management, cutting an estimated $67.4M.
- 253 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2020, up from 207 in Q3 2020.
- Funds reported $9.37B of Ultragenyx Pharmaceutical stock for Q4 2020, up 80% quarter-over-quarter.
- 62 funds opened new Ultragenyx Pharmaceutical positions in Q4 2020 and 16 closed out, a net change of +46 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2020 was T. Rowe Price Associates, an estimated $133M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2020 was Alkeon Capital Management, an estimated $67.4M sold.
Based on aggregated 13F filings for Q4 2020.